TURIMED 10 (4-Chlorodehydromethyltestosterone) is an anabolic steroid which is successfully used for the treatment of male hypogonadism and reduced sperm infertility. Chlorodehydromethyltestosterone is the 4-chloro-substituted derivative of methandienone (dehydromethyltestosterone). This compound is a modified form of Dianabol (Methandrostenolone), whereby it is a combination of the chemical structures of Dianabol and Clostebol (4-chlorotestosterone). This is the reason why its actual chemical name is 4-chlorodehydromethyltestosterone.

TURIMED 10 (4-Chlorodehydromethyltestosterone) is utilized for the treatment of infertility. Infertility is a big problem for many men, as it affects approximately 1 out of every 6 couples. Experts say what in more than half of those cases, the underlying problem is in the male. Sperm counts are falling drastically worldwide – and that haven’t happened overnight, this has been doing so for decades. Scientists don't know the reason for that and are alarmed by this significant global health problem.

As we all know the sperm counts are dependent on high levels of Testosterone hormone, and again, experts are sure that there is some knowledge of links between sperm count and infertility. But beyond this basic knowledge, sperm’s intricacies remain largely undiscovered.

Current statistics showed that sperm counts in men from America, Europe, Australia, and New Zealand have dropped by more than 50 percent in less than 40 years, according to pooled research published in 2018, described by one of its authors as an “urgent wake-up call” for further immediate investigation.

Different factors may affect sperm production and male infertility. The sperm may be reduced in number, less able to swim forwards, become less mobile and be abnormal in their form. These also include current or past infection of the testicles (for example, mumps), current or past infections of another part of the sperm-producing system, such as gonorrhea or other sexually transmitted infections.

There are existing our main causes of infertility in males:

• A hypothalamic or pituitary disorder (1-2%)
• Gonad disorder (30-40%)
• Sperm transport disorder (10-20%)
• Unknown causes (40-50%)

Although a lot of research remains to be performed on the topic of male infertility, many cases still receive an “unknown cause” diagnosis. Male infertility mostly occurs because of abnormal sperm, because of inadequate numbers of sperm, or problems with ejaculation. There are cases when the reason can’t be found after all testes and procedures. In general, sperm can be considered abnormal for two possible reasons: unusually short life span of the sperm and/or low mobility.

Sperm abnormalities may be caused by one or more of the following factors:

• Inflammation of the testicles
• Swollen veins in the scrotum
• Abnormally developed testicles

Reasons for a low sperm count or lack of sperm include one or more of the following factors:

• A pre-existing genetic condition
• Use of alcohol, tobacco or other drugs
• Severe mumps infection after puberty
• Hernia repairs
• Hormone disorder
• Exposure to poisonous chemicals
• Exposure to radiation
• A blockage caused by a previous infection
• Wearing restrictive or tight underwear
• Injury to the groin area.

Which one to choose: Bacteriostatic Water vs. Sterile Water

What is the difference between bacteriostatic water vs. sterile water for injection? Although both of these types of water are sterile, the difference between bacteriostatic water and sterile water is that other sterile waters for injection do not contain a bacteriostatic agent. That means, they are single-dose vials and should be discarded after a single-use.

What is bacteriostatic water?

Bacteriostatic Water (bacteriostatic water for injection) is a highly purified, sterilized water containing 0.9% benzyl alcohol that is used to dilute or dissolve medications to the appropriate consistency for injection. Bacteriostatic water (BW) has a pH of about 5.7. The container can be re-entered multiple times (usually by a sterile needle) and the benzyl alcohol is added to ensure that bacteria does not grow in the water as diluting medications with tainted water can have some severe consequences. The benzyl alcohol in the water makes bacteriostatic water ideal for diluting any drug that will be administered by intramuscular, intravenous, or subcutaneous injection. Once a vial of bacteriostatic water is opened, the benzyl alcohol will usually prevent the growth of bacteria for up to 28 days.

There are not many side effects associated with using bacteriostatic water. Although rarely, but they can occur, those side effects are more related to the drug that is dissolved in the bacteriostatic water. You should never inject bacteriostatic water without mixing in any medications because the benzyl alcohol in it causes the red blood cell lysis. Lysis is the breaking down of a cell or membrane. Other side effects from bacteriostatic water have been reported to include tissue death, venous thrombosis, infection at the injection site, fever, abscess formation as well as a febrile response. In case any of the mentioned side effects are present, it is highly advisable to discontinue the use of bacteriostatic water and consult a doctor.

What is sterile water?

Sterile water is water that has no additives or preservatives added to it. As it cannot transfer pathogens, it is used mainly used in the medical field. Once a vial of sterile water is open, it should be used completely at once or used once and discarded. This is one of the reasons that vials of sterile water usually contain a few milliliters of the liquid.

There are no adverse or bad side effects of using sterile water in small doses, one should never take it intravenously. Although, a small percentage of people report inflammation at the injection site if sterile water is used to dilute peptides that are to be injected intramuscularly. Other side effects can include low blood sodium also known as hyponatremia, fluid overload, allergic reactions (tightness in the chest, swelling of the mouth, face, and lips) fever, redness at the site of injection as well as electrolyte imbalance. In case you experience any of these side effects, you should immediately stop using sterile water for injections and talk to a doctor.

Which one is better?

Bacteriostatic water is better when diluting any medication because it offers better solubility for the most part. Also, if you are experimenting with new peptides, it is always best to use bacteriostatic water to dilute the peptides. In case you have any issue diluting peptides in bacteriostatic water, you should add a small amount of 10% aqueous acetic acid for basic peptides and aqueous ammonia for acidic peptides. Most peptide packages contain mixing instruction. It is always advisable to carefully read them before trying to reconstitute the peptides. It could be potentially harmful to try to reconstitute a peptide meant for mixing with bacteriostatic water with sterile water. You cannot simply replace bacteriostatic water with sterile water and vice versa, as they are not the same thing.

WINIMED 10 (Stanozolol) is a steroid that can be helpful in the treatment of various diseases. WINIMED 10 (Stanozolol) is used in the treatment of hereditary angioedema, which causes episodes of swelling of the face, extremities, genitals, bowel wall, and throat. WINIMED 10 (Stanozolol) may decrease the frequency and severity of such attacks.

Hereditary angioedema (HAE) is an inherited condition characterized by recurrent episodes of non-pruritic, non-pitting, subcutaneous or submucosal swelling without the presence of urticarial lesions. Multiple areas of the body can be involved in these episodes including hands, feet, intestinal wall, genitalia, face, tongue, or larynx. This condition can be very dangerous and that is extremely important to choose the proper treatment. For example, swelling of the pharynx or larynx can be life-threatening due to asphyxia.

Usually, signs and symptoms of HAE start during childhood or puberty and persist throughout life. In general, attacks start with a prodromal sensation of tingling that can be accompanied by a non-pruritic wavy rash followed by slowly progressive swelling that gradually subsides over 48 to 72 hours. More than half of HAE patients have at least 1 oropharyngeal attack during their life.

There are different treatment types of HAE: long–term prophylaxis, short–term prophylaxis, and the treatment of acute attacks. The main long–term goal is to minimize the frequency and severity of angioedema episodes, as being reported, patients suffering from HAE develop 1 to 2 swelling attacks per month on average.

U.S. Food and Drug Administration (FDA) approved C1 inhibitor replacement therapy in 2008, prophylactic or long–term treatment of HAE relied on the use of synthetic 17-α–alkylated androgens: danazol and stanozolol. Long-term prophylaxis should be considered in patients with a history of life-threatening attacks or serious attacks more than once every 3 months.

In double-blind studies, androgens were associated with an increase in the level of C1 inhibitor and a reduction in the number of angioedema attacks. Short-term studies of patients treated with attenuated androgens demonstrated no side effects. However, the side-effect frequencies in patients receiving long-term treatment are still in question. The current study was made to assess the frequencies of various side effects of the attenuated androgen Stanozolol in a population of patients with hereditary angioedema treated for 20 to 40 years. Data on occurred side effects in patients who continued Stanozolol therapy since 1987 were obtained using questionnaire. All patients were evaluated by physical examination, biochemical assays of hepatic function, serum lipids, prostate-specific antigen, and liver ultrasound.

The minimal initial effective daily dosage of WINIMED 10 (Stanozolol) was 0.5 to 2.0 mg, although most patients achieved symptomatic control and decreased the dose and frequency as the frequency of attacks decreased. Treatment-related symptoms developed in 10 of 21 patients. Interruption in WINIMED 10 (Stanozolol) therapy wasn't required because symptoms subsided with a reduction in the WINIMED 10 (Stanozolol) dosage. Side effects included hirsutism, weight gain, menstrual irregularities or postmenopausal bleeding, acne, and mood changes. Liver enzyme assays revealed no persistent abnormalities. Although liver ultrasounds in 8 patients revealed 3 abnormalities deemed unrelated to therapy. Five patients had a reduced high-density lipoprotein, and 2 patients had elevated triglycerides.

The study has shown thatWINIMED 10 (Stanozolol) is a safe and effective drug for the long-term management of hereditary angioedema. During the long-term treatment, patients should be closely supervised with routine clinical, biochemical, and radiologic assessments.

Venous insufficiency is often caused by blood clots. This is a very common disease during which the flow of blood through the veins is blocked, causing blood to pool in the legs. Untreated, venous insufficiency progress into chronic venous insufficiency with symptoms of leg pain, lipodermatosclerosis (inflammation of subcutaneous fat), different skin changes, such as erythema, pigmentation, increased risk of infection, white atrophy and a corona phlebectatica (ankle flare) can appear in the course of the disease. Chronic venous insufficiency (CVI) is a condition then brown-colored indurated patches, known as lipodermatosclerosis, are seen in long-standing cases. In the end-stage of this disease, a venous leg ulcer will occur.

Stanozolol is an androgen and anabolic steroid (AAS) medication which was derived from dihydrotestosterone (DHT). WINIMED SUSP 50 (Stanozolol Water Suspension) has been used in the treatment of venous insufficiency. Different randomized trials noted the improvement in the area of lipodermatosclerosis, reduced skin thickness, and possibly faster ulcer healing rates with WINIMED SUSP 50 (Stanozolol Water Suspension).

For example, patients with chronic venous insufficiency and changes such as dermal pericapillary fibrin cuffs participated in the recent research. It has been suggested that this fibrin deposition is responsible for an oxygen diffusion block, which in turn, leads to local hypoxia and ulcers. Sixty patients with lipodermatoscelerosis were chosen for this double-blind, placebo-controlled, randomized trial. Stanozolol 5 mg or a placebo tablet was given to them twice a day for 6 months. All patients were supplied with below-knee German/Swiss specification class 2 graduated compression stockings. The area of lipodermatosclerosis was measured once a month and transcutaneous oxygen tension within the liposclerotic area was measured every 3-months. The following results were shown: the control group showed a mean reduction in the area of lipodermatosclerosis of 14% (95% c.i.: -2.6-31%) compared with a 28% reduction in area in the active treatment group (95% c.i.: 5.3-46%). Both groups showed no changes in transcutaneous oxygen measurements. The active treatment group experienced more side effects (P less than 0.02, Chi-squared). Although fibrinolytic enhancement caused a reduction in the area of lipodermatosclerosis, no evidence of any effect on a possible oxygen diffusion block was indicated.

WINIMED SUSP 50 (Stanozolol Water Suspension) stimulates blood fibrinolysis and can be successfully utilized for the treatment of the more advanced skin changes in venous disease such as lipodermatosclerosis.